AMETEK Q3 2026 Earnings: Sales Rise 17% as Full-Year Guidance Increases

AMETEK (NYSE: AME) reported Q3 2026 sales of $2.22 billion, up 17% from $1.89 billion a year earlier, while diluted GAAP EPS rose to $1.85 from $1.60 and adjusted EPS increased 17% to $2.21. Adjusted operating margin expanded 60 basis points to 26.8%, and operating cash flow climbed 27% to $560.6 million. Broad-based organic growth, recent acquisitions, and stronger operating execution supported the quarter, with EMG delivering the faster sales and profit growth.

Core Financial Results

AMETEK’s sales and adjusted operating income both reached quarterly records. Adjusted operating income grew faster than sales, reflecting core margin expansion across both operating groups, particularly EMG.

GAAP net income increased approximately 15%, a slower pace than operating income. Higher interest expense, which rose to $39.8 million from $22.5 million, contributed to that difference. Adjusted EPS excluded $0.36 per share of after-tax acquisition-related intangible amortization and transaction and integration costs.

Business and Segment Performance

Both segments benefited from broad-based organic growth and recent acquisitions. EMG produced the stronger operating leverage, with adjusted operating income rising 29% on 20% sales growth, while EIG’s adjusted profit growth was slightly below its sales growth.

EIG’s adjusted margin edged down from 28.9% to 28.7%, but its core margin increased 60 basis points to 29.5% after excluding the dilutive effects of recent acquisitions and foreign exchange. Management attributed the segment’s sales growth to broad organic gains and acquisition contributions.

EMG’s adjusted margin expanded to 27.2% from 25.4%, while its core margin rose 210 basis points to 27.5%. This made EMG the primary source of AMETEK’s consolidated margin improvement during the quarter.

Profitability, Cash Flow, and Balance Sheet

AMETEK’s adjusted operating margin reached 26.8%, up from 26.2%, while adjusted core operating margin expanded 110 basis points to 27.3%. Free cash flow conversion improved to 124% of net income from 113%, indicating that cash generation outpaced reported earnings.

Cash and equivalents increased to $666.2 million at September 30 from $458.0 million at the end of 2025. However, long-term debt rose to $6.03 billion from $1.07 billion, while goodwill increased to $10.21 billion from $7.17 billion alongside the company’s acquisition activity. AMETEK completed its acquisition of Indicor Instrumentation during the quarter, and management expects the acquired businesses to contribute to fourth-quarter and full-year results.

Working-capital balances also increased. Inventories reached $1.37 billion versus $1.11 billion at year-end, while receivables rose to $1.35 billion from $1.12 billion. Despite these increases, quarterly operating and free cash flow remained above the prior-year period.

Earnings Guidance

AMETEK raised its full-year adjusted EPS range to $8.53–$8.57 from $8.20–$8.30. Management attributed the increase to third-quarter execution, its fourth-quarter outlook, and the expected contribution from Indicor Instrumentation. The company now expects full-year sales to grow by a mid-teens percentage from 2025.

Recent Insider Transactions

During the latest six-month period provided, insiders purchased 11,368 shares across three transactions and sold 6,608 shares in one transaction, resulting in net purchases of 4,760 shares. That represented approximately 0.50% of the roughly 901,000 shares held by insiders.

Stock awards and derivative conversions are distinct from open-market purchases and sales and should be interpreted separately.

Risks Investors Should Monitor

• Acquisition and integration demands: Recent acquisitions contributed to growth and the higher outlook, but successful integration is necessary to realize the expected benefits from Indicor and other acquired businesses.
• Higher debt and financing costs: Long-term debt increased substantially from year-end, while quarterly interest expense rose to $39.8 million from $22.5 million. Additional financing costs could limit how much operating growth reaches net income.
• GAAP and adjusted earnings divergence: Acquisition-related amortization and transaction and integration costs accounted for a $0.36-per-share adjustment in Q3. Continued acquisition activity may keep adjusted earnings above GAAP results.
• Working-capital growth: Inventories and receivables increased from year-end levels. Investors should monitor whether AMETEK can maintain its current cash conversion as the larger business and recent acquisitions are integrated.
• Fourth-quarter execution: The outlook calls for low-20% sales growth but 12% to 14% adjusted EPS growth, making margins, acquisition dilution, and financing costs important variables for the quarter.

Summary

AMETEK’s Q3 2026 results combined 17% sales growth with higher adjusted margins and a 27% increase in operating cash flow. EMG supplied the strongest operating leverage, while organic demand and acquisitions supported both segments. The raised full-year EPS outlook reflects that momentum and the expected Indicor contribution, but higher debt, interest expense, and acquisition-related adjustments remain important areas to monitor.